Literature DB >> 12093695

Preadult stage parasites and multiple timed exposure to infective larvae are involved in development of limb edema in Brugia malayi-infected Indian leaf monkeys (Presbytis entellus).

P K Murthy1, M A Khan, H B Rajani, V M L Srivastava.   

Abstract

The pathogenesis of filarial limb edema is not known. The role of parasitological variables and parasite-mediated phenomena in the development of limb edema was investigated in the Presbytis entellus-Brugia malayi model. Infection was initiated with subcutaneous inoculation of infective third-stage larvae (L(3)), and the animals were reexposed to different doses of L(3) at the prepatent, patent, and diminishing microfilaremia (0 to 5% of peak microfilaremia count) stages of infection. A large L(3) inoculum size and repeated inoculation in the ankle region during the prepatent, patent, and diminishing microfilaremia stages of infection were found to be necessary for reproducible induction of limb edema. The preadult stage of the parasite was found to be the most potent inducer of limb edema, followed by L(5) and L(4). The presence of the proinflammatory cytokines tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in edema fluid in the leg receiving the parasite challenge indicated that the limb edema development was due to parasite-mediated cytokine responses. The absence of bacterial infection or anti-streptolysin O titer in the edema fluid and blood indicated that bacterial infection is not necessary for the development of limb edema.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093695      PMCID: PMC120029          DOI: 10.1128/cdli.9.4.913-918.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  27 in total

1.  Dot-ELISA for diagnosis of lymphatic filariasis.

Authors:  A Tandon; P K Murthy; R P Saxena; A B Sen; K C Saxena
Journal:  Indian J Med Res       Date:  1988-05       Impact factor: 2.375

2.  Studies with Brugia pahangi. II. The effect of repeated infection on parasite levels in cats.

Authors:  D A Denham; T Ponnudurai; G S Nelson; R Rogers; F Guy
Journal:  Int J Parasitol       Date:  1972-11       Impact factor: 3.981

3.  "Filarial" adenolymphangitis without filarial infection.

Authors:  D G Addiss; M L Eberhard; P J Lammie
Journal:  Lancet       Date:  1994-03-05       Impact factor: 79.321

4.  Chronic infection of cats with Brugia malayi and streptococcus.

Authors:  A Ewert; J C Reitmeyer; D Folse
Journal:  Southeast Asian J Trop Med Public Health       Date:  1980-03       Impact factor: 0.267

5.  Inflammatory cytokines following diethylcarbamazine (DEC) treatment of different clinical groups in lymphatic filariasis.

Authors:  M Haarbrink; A J Terhell; G K Abadi; Y Mitsui; M Yazdanbakhsh
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Nov-Dec       Impact factor: 2.184

6.  Regulatory cytokines in the lymphatic pathology of athymic mice infected with Brugia malayi.

Authors:  U R Rao; A C Vickery; B H Kwa; J K Nayar
Journal:  Int J Parasitol       Date:  1996-05       Impact factor: 3.981

7.  The relationship between infection and disease in Wuchereria bancrofti infection in Ghana.

Authors:  J O Gyapong
Journal:  Trans R Soc Trop Med Hyg       Date:  1998 Jul-Aug       Impact factor: 2.184

8.  Effects of presensitization on the development of lymphatic lesions in Brugia pahangi-infected jirds.

Authors:  T R Klei; F M Enright; D P Blanchard; S A Uhl
Journal:  Am J Trop Med Hyg       Date:  1982-03       Impact factor: 2.345

9.  Parasitologic and clinical features of bancroftian filariasis in a community in East Sepik Province, Papua New Guinea.

Authors:  J W Kazura; R Spark; K Forsyth; G Brown; P Heywood; P Peters; M Alpers
Journal:  Am J Trop Med Hyg       Date:  1984-11       Impact factor: 2.345

10.  Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis.

Authors:  S P Pani; J Yuvaraj; P Vanamail; V Dhanda; E Michael; B T Grenfell; D A Bundy
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Jan-Feb       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.